EUMelaReg ADJU-SEQ subanalysis accepted at ESMO congress 2023
As part of the EUMelaReg ADJU-SEQ project a subanalysis was performed and submitted as an abstract to the ESMO Congress. We are pleased to announce that this subanalysis has been accepted for poster presentation at the ESMO Congress 2023, to be held in Madrid, October 20-24, 2023. (Abstract title: Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment. A EUMelaReg real-world evidence study.)
The study focus on patients with resected, high-risk, node-positive melanoma and a BRAF V600 mutation, where options for adjuvant therapy include either immunotherapy or targeted combination therapy with dabrafenib plus trametinib. Little is known about the outcomes of adjuvant systemic therapy beyond clinical trials in general and the similarities/differences between immunologic and targeted therapies in particular. EUMelaReg has collected and analyzed real-world data to retrospectively examine the outcomes of patients receiving the different therapy options in the adjuvant setting.